drugset / Trial / NCT00358436

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

NCT00358436

Phase 3 Completed 804 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.

Timeline

Start
2006-08
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclidinium Small molecule 200 ug Inhaled